Propanc Biopharma issues $33K convertible note; due March 2025, conversion at $0.0003

Propanc Biopharma, Inc.

Issued convertible promissory note with $33,000 principal ($30,000 net) to GS Capital Partners, LLC.
Conversion price set at $0.0003 per share, dropping to $0.0001 if stock trades below that for 5 consecutive days.
Maturity March 25, 2025; 8% annual interest, increasing to 24% on default.
Proceeds used for general working capital; prepayment options with premiums from 110% to 125% in first 180 days.
Note issued under Regulation D as unregistered securities exempt under Section 4(a)(2) of Securities Act.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.